Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $30.0b | $220.00 | +0.1% | 484.1K |
 NBIX | Neurocrine Biosciences Inc | $16.9b | $157.66 | +2.1% | 959.9K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $249.61 | -4.2% | 2.2M |
 AXSM | Axsome Therapeutics, Inc | $11.2b | $208.33 | +0.8% | 308.6K |
 CYTK | Cytokinetics Inc. | $10.5b | $79.53 | +2.3% | 1.1M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $8.5b | $375.00 | +2.5% | 413.9K |
 ALKS | Alkermes Inc. plc | $8.2b | $49.16 | -0.1% | 488.9K |
 TGTX | TG Therapeutics, Inc. | $7.1b | $55.28 | -0.8% | 792.5K |
 XENE | Xenon Pharmaceuticals Inc | $6.0b | $62.51 | +5.6% | 1.2M |
 DFTX | Definium Therapeutics, Inc. Common Shares | $5.8b | $43.51 | -2.3% | 1.4M |
 PTCT | PTC Therapeutics, Inc. | $5.7b | $72.70 | -1.0% | 395.6K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.7b | $36.19 | -0.3% | 809.3K |
 ACAD | Acadia Pharmaceuticals Inc. | $4.4b | $29.68 | -3.3% | 1.1M |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.7b | $24.46 | -1.4% | 604.1K |
 ALMS | Alumis Inc. Common Stock | $3.6b | $24.00 | -1.4% | 499.3K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $3.0b | $5.50 | -0.5% | 58.4K |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.7b | $44.92 | -1.0% | 451.4K |
 ATAI | AtaiBeckley Inc. Common Stock | $2.7b | $7.38 | -0.8% | 3.5M |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $2.3b | $37.47 | -1.1% | 1.7M |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $2.0b | $39.40 | +1.8% | 640.9K |
 BHVN | Biohaven Ltd. | $2.0b | $16.94 | +18.8% | 14.8M |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $2.0b | $52.53 | +2.7% | 229.4K |
 GHRS | GH Research PLC Ordinary Shares | $1.9b | $29.03 | +0.2% | 132.0K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.8b | $33.03 | -1.1% | 557.0K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.7b | $6.12 | -3.1% | 1.1M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $1.1b | $48.16 | -1.4% | 228.2K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.1b | $27.51 | +0.1% | 466.0K |
 ANRO | Alto Neuroscience Inc. | $1.1b | $36.52 | +0.6% | 239.8K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $17.03 | +0.1% | 164.6K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $4.97 | -3.5% | 1.9M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $76.73 | -3.8% | 65.4K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.6b | $17.02 | -0.3% | 371.3K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.6b | $12.49 | +3.2% | 824.9K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.6b | $4.55 | -1.1% | 411.9K |
 HELP | Cybin Inc. Common Stock | $484.7m | $13.80 | -2.7% | 1.5M |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $463.6m | $5.31 | +5.9% | 3.2M |
 PRTA | Prothena Corporation plc Ordinary Shares | $436.1m | $9.26 | -1.8% | 244.3K |
 OVID | Ovid Therapeutics Inc. Common Stock | $434.9m | $2.92 | -1.4% | 1.0M |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $342.3m | $2.51 | -0.4% | 200.3K |
 VNDA | Vanda Pharmaceuticals Inc. | $314.5m | $5.34 | -1.9% | 655.6K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $303.9m | $1.55 | +4.0% | 481.0K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $260.9m | $3.41 | -3.7% | 745.6K |
 AVXL | Anavex Life Sciences | $254.8m | $3.28 | -9.1% | 1.1M |
 ACIU | AC Immune SA | $222.9m | $2.83 | -2.7% | 264.3K |
 NERV | Minerva Neurosciences, Inc | $185.0m | $5.43 | +8.9% | 367.8K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $181.3m | $3.44 | -0.7% | 246.9K |
 ACOG | Alpha Cognition Inc. Common Stock | $180.3m | $9.45 | -3.5% | 241.8K |
 NGEN | NervGen Pharma Corp. Common stock | $174.5m | $2.21 | +6.2% | 456.5K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $170.0m | $13.61 | -0.1% | 490.0K |
 ALEC | Alector, Inc. Common Stock | $167.6m | $2.48 | +4.2% | 958.7K |